QNCX - NASDAQ

Quince Therapeutics, Inc.

QNCX·NASDAQ

$1.36

+0.0000%

HealthcareBiotechnology

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$75.89M

EPS-1.3100

P/E Ratio-1.04

Earnings Date03/23/2026

114.48M

Assets

-36%

3Y-14.0%

5Y-8.0%

10Y+1383.0%

84.33M

Total Liabilities

-11%

3Y+476.0%

5Y+848.0%

10Y+201.0%

30.15M

Total Equity

-65%

3Y-75.0%

5Y-74.0%

10Y-249.0%

Quince Therapeutics, Inc. Funding & Solvency Profile

QNCX · NASDAQ

Current Assets

Cash & Cash Equivalents6.21M

Net Receivables882.00K

Inventory0.00

Other Current Assets84.00K

Total Current Assets44 M

Non-Current Assets

Property, Plant & Equipment813.00K

Goodwill & Intangible Assets60.05M

Long-Term Investments78.00K

Other Non-Current Assets9.51M

Total Non-Current Assets10 M

Total Assets

114.48M

Financial Health Analysis

Current Ratio

6.05x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.80x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

37 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

38% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Quince Therapeutics, Inc. Balance Sheet

QNCX • NASDAQ

Quince Therapeutics, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	6.2M	20.8M	44.6M	69.7M	66.8M	51.2M	24.9M	7.3M
Short-Term Investments	34.6M	54.3M	45.6M	37.1M	67M	48.7M	46.8M	0.0
Cash & Short-Term Investments	40.8M	75.1M	90.2M	106.8M	133.8M	99.9M	71.7M	7.3M
Net Receivables	882K	993K	0.0	1.1M	0.0	0.0	0.0	0.0
Accounts Receivables	882K	0.0	0.0	1.1M	0.0	0.0	0.0	0.0
Other Receivables	0.0	993K	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	2.3M	1.3M	1.2M	3.4M	3.3M	5.5M	47K	51K
Other Current Assets	84K	81K	2.4M	367K	694K	688K	821K	143K
Total Current Assets	44M	77.4M	93.7M	111.7M	137.9M	106.1M	72.6M	7.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	813K	619K	684K	1.4M	1.1M	1.3M	283K	122K
Goodwill	0.0	17.6M	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	60M	63.7M	5.9M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	60M	81.3M	5.9M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	78K	78K	3.6M	19.9M	50.5M	16.8M	0.0	0.0
Tax Assets	0.0	12.3M	-3.6M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	9.5M	8.5M	3.6M	194K	39K	217K	10K	59K
Total Non-Current Assets	70.4M	102.8M	10.2M	21.6M	51.6M	18.3M	293K	181K
Total Assets	114.5M	180.2M	103.9M	133.2M	189.5M	124.4M	72.9M	7.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.9M	2M	570K	4.9M	3.6M	3.1M	495K	517K
Accounts Payable	2.9M	2M	570K	4.9M	3.6M	3.1M	495K	517K
Accrued Expenses	4M	2.3M	1.1M	8.4M	2.4M	5.8M	962K	1.2M
Short Term Debt	0.0	64K	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	96K	0.0	453K	741K	238K	0.0	0.0	0.0
Other Current Liabilities	308K	5.1M	916K	180K	10.8M	0.0	0.0	0.0
Total Current Liabilities	7.3M	9.6M	3.1M	14.2M	17M	8.9M	1.5M	1.8M
NON-CURRENT LIABILITIES
Long Term Debt	14.3M	13.4M	0.0	0.0	0.0	0.0	0.0	7.2M
Deferred Tax Liabilities (Non-Current)	5M	17.6M	248K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	57.4M	54.2M	0.0	0.0	0.0	0.0	0.0	19.1M
Total Non-Current Liabilities	77.1M	85.5M	248K	420K	208K	3.1M	495K	26.2M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	-3.1M	-495K	0.0
Capital Lease Obligations	490K	321K	453K	1.2M	446K	0.0	0.0	0.0
Total Liabilities	84.3M	95.1M	3.3M	14.6M	17.2M	8.9M	1.5M	28M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	-220K	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	124.4M	104M	17.2M
Common Stock	44K	43K	36K	30K	29K	27K	22K	3K
Additional Paid-In Capital	406.6M	401.6M	389.1M	355.2M	318.6M	185.2M	239K	60K
Retained Earnings	-376.5M	-319.6M	-288.3M	-236.6M	-146.7M	-69.8M	-32.8M	-20.3M
Accumulated Other Comprehensive Income/Loss	-35K	3M	-289K	-79K	313K	60K	-49K	-17.2M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	7K	6K
Total Stockholders' Equity	30.1M	85.1M	100.6M	118.6M	172.3M	115.5M	71.4M	-20.3M
Total Equity	30.1M	85.1M	100.6M	118.6M	172.3M	115.5M	71.4M	-20.3M
SUMMARY
Total Liabilities & Equity	114.5M	180.2M	103.9M	133.2M	189.5M	124.4M	72.9M	7.7M
Total Investments	34.7M	54.4M	49.2M	57M	117.4M	65.4M	46.8M	0.0
Total Debt	14.8M	13.8M	453K	1.2M	446K	0.0	0.0	7.2M
Net Debt	8.6M	-6.9M	-44.1M	-68.6M	-66.4M	-51.2M	-24.9M	-172K
Shares Outstanding	53,713,798	53,713,798	53,713,798	53,713,798	53,713,798	53,713,798	53,713,798	53,713,798

SEC Filings

QNCX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 29, 2026	January 29, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 17, 2025	October 17, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 26, 2025	September 25, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 11, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 11, 2025	August 11, 2025	2025	View Filing
S-3 S-3 N/A	July 25, 2025	July 25, 2025		View Filing
8-K 8-K 2025 N/A	July 16, 2025	July 16, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 13, 2025	June 12, 2025	2025	View Filing

Showing 1 to 10 of 99 filings

Related Guides

Blog Categories

Continue your QNCX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.